- In April 2024, Alnylam Pharmaceuticals announced expanded global access to Amvuttra (vutrisiran), its RNA interference (RNAi) therapy administered via subcutaneous injection for hereditary transthyretin-mediated amyloidosis (hATTR). This move supports wider patient reach across North America, Europe, and Asia-Pacific and reflects the company’s focus on delivering convenient, long-acting genetic therapies with improved patient compliance. The initiative underscores Alnylam’s leadership in RNA therapeutics and the growing adoption of subcutaneous delivery in chronic rare disease treatment
- In March 2024, Ionis Pharmaceuticals reported positive results from Phase 3 trials of Tofersen, an antisense oligonucleotide therapy for SOD1-ALS, administered subcutaneously. The findings showed significant slowing of disease progression and better tolerability due to the subcutaneous route. This development marks a critical milestone in neurodegenerative disease management and reinforces the potential of self-administered nucleic acid drugs in complex indications
- In February 2024, Moderna, Inc. announced plans to expand its mRNA platform to include subcutaneously administered treatments targeting latent viral infections. The company’s pipeline now includes mRNA-based therapies for CMV and EBV, exploring alternative delivery routes beyond intramuscular injections. This move signals growing interest in subcutaneous administration for therapeutic mRNA beyond vaccines and represents a strategic pivot toward broader chronic disease applications
- In January 2024, Silence Therapeutics entered into a partnership with Hansoh Pharma to co-develop and commercialize SLN360, an siRNA therapy targeting elevated lipoprotein(a), in the Asia-Pacific region. The therapy is designed for subcutaneous delivery and addresses unmet needs in cardiovascular risk management. This collaboration highlights increasing cross-border investments in RNA-based therapies and the expanding role of subcutaneous modalities in managing widespread chronic diseases
